Rumpus Vascular

Rumpus Vascular is a clinical-stage biotechnology company dedicated to developing innovative therapies for rare orphan vascular diseases. A subsidiary of Rumpus Therapeutics, the company focuses on addressing significant unmet medical needs in pediatric and adult populations with vascular malformations. Its lead candidate, RV-001, is a topical formulation of the mTOR inhibitor sirolimus, specifically engineered for the treatment of cutaneous venous malformations. The program has progressed through Phase 2 clinical testing, aiming to provide a localized treatment option that avoids the systemic toxicities associated with oral mTOR inhibitors. The company's leadership team brings extensive experience from major pharmaceutical firms, focusing on a lean, asset-centric development model.